IP Library › Granted Patent US 8,492,105
Granted Patent B2
US 8,492,105 · App. 13/618,417 · Granted Jul 23, 2013

Screening method for an insulin resistance improving agent or a therapeutic agent for diabetes

Inventors: Kentarou Doi (Kawasaki, JP); Takayoshi Kinoshita (Osaka, JP); Atsushi Tomonaga (Kawasaki, JP); Hajime Sugiyama (Kawasaki, JP); Matsuyo Wada (Kawasaki, JP)
Assignee: Fujitsu Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,105
App. No.
13/618,417
Granted
Jul 23, 2013
Kind
B2
Abstract

A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes.

Claims (9)

1. A screening method for at least one of an insulin resistance improving agent and a therapeutic agent for diabetes, the screening method comprising:

determining the presence or absence of interaction between signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase 2 (ERK2) to select a compound having a phosphorylation inhibitory activity, and

evaluating the compound for whether X>Y where X denotes a Homeostasis model assessment-Insulin Resistance (HOMA-IR) value of a diabetes model animal to which the compound has not been administered and Y denotes a HOMA-IR value of a diabetes model animal to which the compound has been administered,

wherein the determining is performed by preparing a mixture by mixing together at least the compound, the STAT3 whose Ser727 is not phosphorylated, and an enzyme that phosphorylates the STAT3; reacting the STAT3 whose Ser727 has been phosphorylated in the mixture with an antibody that binds to a phosphorylated site of the STAT3 whose Ser727 has been phosphorylated; and screening for the compound present in the mixture containing the STAT3 to which the antibody has not bound, as a compound having the phosphorylation inhibitory activity.

2. The screening method according to claim 1 , wherein the preparing comprises phosphorylating the Ser727 of the STAT3 contained in the mixture.

3. The screening method according to claim 1 , wherein the reacting comprises detecting the antibody binding to the phosphorylated site of the STAT3 whose Ser727 has been phosphorylated.

4. The screening method according to claim 3 , wherein the detecting is performed with IgG derived from a host of the antibody binding to the phosphorylated site of the STAT3 whose Ser727 has been phosphorylated.

5. The screening method according to claim 4 , wherein the IgG is detected with a label bound thereto.

6. The screening method according to claim 1 , wherein the screening is performed by determining the presence or absence of the phosphorylation inhibitory activity of the compound.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2012
From: DOI, KENTAROU; KINOSHITA, TAKAYOSHI; TOMONAGA, ATSUSHI; SUGIYAMA, HAJIME; WADA, MUTSUYO
To: FUJITSU LIMITED
Reel/Frame 028978/0726 →
Priority Claims (1)
JP 2009-039997 · Feb 23, 2009 · national
Continuity (3)
Division 13214712 · Aug 22, 2011
Continuation PCTJP2010052765 · Feb 23, 2010
Related Publication 20130022993A1 · Jan 24, 2013